Immunotherapy of lymphoma through in situ manipulation of an involved lymph node can allow for development of an active anti-lymphoma immune response without the need for ex vivo handling or immunization with a specific antigen. A comprehensive and successful approach to in situ immunization in lymphoma would require effective presentation of antigen by the lymphoma cells or professional antigenpresenting cells, activation of lymphoma-specific T cells and suppression of the regulatory arm of the immune response to enhance development of a sustained anti-lymphoma T cell response. The current proposal evaluating a novel approach to in situ immunization is based on scientific advances made possible through the UI/MC SPORE over the prior funding period. The overall hypothesis is that in situ immunization with nanoparticles will allow for induction and maintenance of a robust anti-lymphoma immune response with acceptable toxicity. To test this hypothesis, this project will assess the effect of intratumoral injection of nanoparticles (NPs) containing doxorubicin (dox) on lymphoma cells, the immune microenvironment, and the anti-lymphoma immune response in animal models and in a Phase I clinical trial in subjects with lymphoma. It will then assess the effect of intratumoral injection of NPs containing both dox and the toll-like receptor 9 (TLR9) agonist CpG ODN (CpG dox NPs) in mice and humans. Finally, it will assess how agents capable of maintaining the T cell response impact on the success of in situ immunization with NP. Successful development of such an approach to in situ immunization would be of great significance as a way to treat lymphoma, and could be applicable to other cancers as well.

Public Health Relevance

There continues to be a need for new treatments for lymphoma. In situ immunization holds considerable promise as a way to induce a long term, anti-lymphoma immune response that results in clinical benefit for patients. The proposed studies are designed to explore a novel approach to in situ immunization that, if successful, could represent a novel approach to therapy for lymphoma and other cancers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Iowa
Iowa City
United States
Zip Code
Thompson, Carrie A; Yost, Kathleen J; Maurer, Matthew J et al. (2018) Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol 36:749-756
Naik, Shruthi; Galyon, Gina D; Jenks, Nathan J et al. (2018) Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer. Mol Cancer Ther 17:316-326
Thanarajasingam, Gita; Maurer, Matthew J; Farooq, Umar et al. (2018) Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol 183:149-152
Kleinstern, Geffen; Maurer, Matthew J; Liebow, Mark et al. (2018) History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8:73
Saad Aldin, Ehab; McNeely, Parren; Menda, Yusuf (2018) Posterior Reversible Encephalopathy Syndrome on 18F-FDG PET/CT in a Pediatric Patient With Burkitt's Lymphoma. Clin Nucl Med 43:195-198
Link, Brian K; Day, Bann-Mo; Zhou, Xiaolei et al. (2018) Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol :
Ebeid, Kareem; Meng, Xiangbing; Thiel, Kristina W et al. (2018) Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol 13:72-81
Holahan, Heather M; Farah, Ronda S; Fitz, Sara et al. (2018) Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol 57:1314-1319
Maurer, Matthew J; Ghesquières, Hervé; Link, Brian K et al. (2018) Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol 36:1603-1610
Huet, Sarah; Tesson, Bruno; Jais, Jean-Philippe et al. (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549-561

Showing the most recent 10 out of 387 publications